AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Update

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the recipient of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 7,013,343 shares, a growth of 5,016.3% from the May 14th total of 137,078 shares. Based on an average trading volume of 123,199,850 shares, the short-interest ratio is currently 0.1 days. Approximately 48.2% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets decreased their price objective on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, AIM ImmunoTech has an average rating of “Buy” and a consensus price target of $9.00.

AIM ImmunoTech Stock Down 22.3%

Shares of NYSEAMERICAN AIM opened at $0.40 on Wednesday. The firm has a market cap of $5.87 million, a price-to-earnings ratio of -0.06 and a beta of 1.18. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.10. AIM ImmunoTech has a 52-week low of $0.21 and a 52-week high of $20.35. The business’s 50 day moving average is $0.48 and its two-hundred day moving average is $0.92.

AIM ImmunoTech (NYSEAMERICAN:AIM) last announced its earnings results on Friday, May 15th. The company reported ($0.69) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million during the quarter. Research analysts predict that AIM ImmunoTech will post -0.63 EPS for the current year.

Institutional Trading of AIM ImmunoTech

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sabby Management LLC purchased a new stake in AIM ImmunoTech in the third quarter valued at approximately $79,000. DRW Securities LLC raised its position in AIM ImmunoTech by 60.6% in the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock valued at $79,000 after purchasing an additional 26,254 shares during the period. Finally, Corient Private Wealth LLC purchased a new stake in AIM ImmunoTech in the second quarter valued at approximately $87,000. Hedge funds and other institutional investors own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.